Endo will have a difficult time finding a buyer. The CEO and THE BOARD have embarked on a foolish strategy that has failed in the history of bio-pharma companies. There were NO buyers for AMS when Endo's board bought it. So, any buyer of Endo now has to discount a break up based on a "no sale" for AMS. Who on this board endorsed this?
They paid way more for their various acquisitions than they were worth with the thought there were so many synergies but are finding they can't influence the market with all their products and are left with overvalued businesses
The fact that the Board didn't know that before the acquisitions is very troubling. Anyone whose been in this industry for any length of time would have known that. I suspect one director thought this was JNJ and ENDP could be a company of companies.